Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options.
about
Nonalcoholic steatohepatitis: emerging targeted therapies to optimize treatment optionsFuture therapy of portal hypertension in liver cirrhosis - a guess.Hemodynamic Effects of the Non-Peptidic Angiotensin-(1-7) Agonist AVE0991 in Liver CirrhosisCharacterization of ACE and ACE2 Expression within Different Organs of the NOD MouseEmerging markers in cardiovascular disease: where does angiotensin-converting enzyme 2 fit in?Normal and abnormal pulmonary arteriovenous shunting: occurrence and mechanisms.Fontan Liver Disease: Review of an Emerging Epidemic and Management Options.Superior Mesenteric Arterial Flow Pattern is Associated with Major Adverse Events in Adults with Fontan Circulation.Renin angiotensin system in liver diseases: Friend or foe?Modulation of angiotensin II signaling in the prevention of fibrosis.Plasma renin concentration represents an independent risk factor for mortality and is associated with liver dysfunction in patients with cirrhosis.Angiotensin II or epinephrine hemodynamic and metabolic responses in the liver of L-NAME induced hypertension and spontaneous hypertensive rats.Nonalcoholic fatty liver disease and the renin-angiotensin system blockers in the patients with chronic kidney disease.The Outcome of Cirrhotic Patients with Ascites Is Improved by the Normalization of the Serum Sodium Level by Tolvaptan.Balancing effect of Biejiajian Oral Liquid () on ACE-Ang II-AT1R axis and ACE2-Ang-(1-7)-Mas axis in rats with CCl4-induced hepatic fibrosis.Interference of angiotensin II and enalapril with hepatic blood flow regulation.Loss of angiotensin converting enzyme II (ACE2) accelerates the development of liver injury induced by thioacetamide.Targeting the renin-angiotensin system in liver fibrosis.The angiotensin-converting enzyme inhibitor captopril rescues mice from endotoxin-induced lethal hepatitis.Response to tolvaptan and its effect on prognosis in cirrhotic patients with ascites.Role of the renin-angiotensin system in hepatic fibrosis and portal hypertension.Activation of RAAS in a rat model of liver cirrhosis: no effect of losartan on renal sodium excretionLiver Toxicology
P2860
Q26796448-628645E1-B682-46BE-880D-B4CB13572E4CQ34446521-71B95C5D-F333-4AED-859A-48B5D098957FQ35787734-3F9E1637-2546-4BB1-B233-959EDD599F34Q37729150-DBB25097-B6D0-49E3-B98A-CA2E3821FCDCQ38083745-07E0DC67-315C-4F48-A164-2DEE580F5F15Q38086269-90026683-8116-47B8-89C3-E240EDA25D2DQ38592964-CB310E33-F6AA-4B3B-A01B-E0C537D749D9Q38795075-4BCE7C1E-3500-467F-949B-92C9968BCF3CQ39360840-980DCD52-294B-41AD-9961-C3840E175EFCQ40362636-9F05062D-6FD0-4F1D-9FEC-CA1BD950211BQ40761529-BB4081F7-2481-466B-AB66-87DDB2E14DA7Q42196629-F44258BE-5977-4386-AF92-040FF1D3CCF9Q46083342-281E8262-98EF-460E-92E2-FE0E4CD26516Q47104649-B1767136-F814-4DD8-AEA4-2A0934A538E8Q48506246-18834713-DDF5-4F12-BFF2-F657EC31EA41Q48638828-CC3C9469-83F4-4524-9EC2-BCE54A8018B0Q50223405-260F6A44-4001-4992-819B-1688079FEF6CQ50238685-EC5594B9-DDFB-413D-88C4-512ED63E8A7DQ51094217-39E231AB-5608-4A56-9E8A-6C6DE9B6B32DQ51793798-392BA916-BC97-4243-B19F-B15D308A3B2EQ55363090-52AA0908-9D71-411B-8B71-B60EB22F2501Q57108060-21E21F06-569D-4123-A0CE-66D5AC85E604Q57724726-E7661FD7-A2BA-4428-9114-2F2043175D85
P2860
Update on new aspects of the renin-angiotensin system in liver disease: clinical implications and new therapeutic options.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Update on new aspects of the r ...... s and new therapeutic options.
@en
type
label
Update on new aspects of the r ...... s and new therapeutic options.
@en
prefLabel
Update on new aspects of the r ...... s and new therapeutic options.
@en
P2093
P2860
P356
P1433
P1476
Update on new aspects of the r ...... ns and new therapeutic options
@en
P2093
Josephine A Grace
Kai Yan Mak
Louise M Burrell
Peter W Angus
P2860
P304
P356
10.1042/CS20120030
P407
P577
2012-08-01T00:00:00Z